HSF1 and breast cancer: Because HSF1 is a pro-survival factor associated with resistance to treatment in multiple cancers (Dong et al, 2019, 2020), development of small-molecule inhibitors is providing the opportunity to test new combinatorial strategies to target resistant breast cancers.